This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Roger C. Bone, MD

JAMA. 1994;271(18):1447-1448.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Physicians in the United States will soon be provided with a new, selective, long-acting β₂-adrenergic aerosol, salmeterol xinafoate,^1,2 for the treatment of asthma. In this issue of THE JOURNAL, D'Alonzo et al³ show that salmeterol inhaled twice daily compared with albuterol inhaled four times daily provides more effective bronchodilation in patients requiring maintenance therapy. Additionally, there was no deterioration in asthma control with the use of salmeterol throughout a 3-month period. Other studies have reported similar results.⁴ . . . [Full Text PDF of this Article]

Author Affiliations
From the Office of the President, Medical College of Ohio, Toledo.

Footnotes
Dr Bone is a Consulting Editor of JAMA. He has received honoraria for participating in continuing medical education programs supported by unrestricted grants from Glaxo Pharmaceuticals, Research Triangle Park, NC, the manufacturer of salmeterol.

Address correspondence to Office of the President, Medical College of Ohio, 3000 Arlington Ave, Toledo, OH 43614 (Dr Bone).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?